Key Stats for CVS Health Stock
- Past week’s performance: 4.8%
- 52-week range: $58 to $85
- Valuation model target price: $98
- Implied upside: 18.8% over 2.7 years
Value your favorite stocks like CVS with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
CVS Health Corporation (CVS) shares gained about 4.8% over the past week, and the stock now sits near its 52-week high of $85. The recovery from a low of $58 earlier in the year represents a meaningful rebound, but significant operational challenges remain as Q1 2026 results are due on May 6.
One of the most pressing issues is a potential labor dispute at CVS distribution centers. Workers represented by the Teamsters union authorized a strike in April. A strike authorization does not guarantee a work stoppage, but it increases negotiating pressure on management and raises the risk of supply chain disruptions that could affect pharmacy fulfillment for customers nationwide.
On the positive side, CVS and Google Cloud announced a new strategic partnership in March to improve healthcare consumer engagement. The agreement involves using Google’s cloud technology and artificial intelligence to personalize health experiences for CVS customers across its pharmacy and insurance platforms.
CVS also reached a proposed settlement with the Federal Trade Commission over insulin pricing practices at its pharmacy benefit management unit. The FTC settlement removes one legal overhang but underscores the ongoing regulatory scrutiny facing pharmacy benefit managers, which are intermediaries that negotiate drug prices between insurers and pharmaceutical manufacturers.
Going forward, management will need to address both the labor situation and Medicare Advantage profitability questions when reporting Q1 results on May 6.
See analysts’ growth forecasts and price targets for CVS (It’s free) >>>
Is CVS Health Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): 3.4%
- Operating Margins: 4%
- Exit P/E Multiple: 9.5x
Based on these inputs, the model estimates a target price of $98, implying an 18.8% total return from the current share price of $82 and a 6.7% annualized return over the next 2.7 years.
A 6.7% annual return is below the 10% threshold most investors would consider compelling on its own. But CVS also pays a quarterly dividend that adds approximately 3.3% annually, so the total return including dividends is more meaningful than the capital appreciation figure alone. CVS is not a growth stock, and the model does not price it as one.
The 3.4% revenue growth assumption reflects CVS’s guidance of at least $400 billion in total 2026 revenue. That is an enormous revenue base, but slow growth at scale is the trade-off. The insurance unit Aetna has faced elevated medical costs and margin compression in the Medicare Advantage business, which drags on profitability across the entire enterprise.
The 4.0% operating margin assumption is a step up from the current 2.5% margin over the past twelve months. Reaching that target requires better cost discipline in the insurance segment and steady growth in pharmacy services. And the 9.5x exit P/E multiple reflects a company that the market values as a mature, value-oriented healthcare business rather than a growth platform.
Street analysts have set an average target of $97, which aligns almost exactly with the model’s $97.56. That tight alignment confirms that the model’s assumptions reflect mainstream expectations rather than outlier optimism, and investors seeking steady income with modest capital appreciation may find the current setup worthwhile.
What’s Driving CVS Stock Going Forward?
The Teamsters labor situation is the most immediate near-term risk. A work stoppage at distribution centers would slow pharmacy fulfillment and create operational disruptions across CVS’s retail network. Management must resolve the contract dispute quickly, because any extended walkout could hurt both customer service levels and quarterly financial results.
The Google Cloud partnership is a meaningful long-term catalyst. CVS is actively trying to transform from a pharmacy retailer into a fully integrated health services company. Artificial intelligence tools and personalized health engagement could improve customer retention across both the pharmacy and Aetna insurance segments, and a technology partnership with Google adds credibility to that transformation strategy.
Medicare Advantage remains the central profitability challenge. Medicare Advantage is a government-funded health insurance program administered by private insurers like Aetna, and analysts expect benefit reductions in 2027 as insurers work to restore margins after years of elevated medical costs. CVS will need to outline a clear recovery plan when it reports Q1 results on May 6.
Aetna’s decision to standardize prior authorization, which is the process where insurers review and approve medical treatments before they occur, also matters competitively.
CVS has standardized 88% of its prior authorization volume and joined other major insurers in adopting a common industry standard. Reducing administrative friction for healthcare providers strengthens Aetna’s relationships with hospital networks and physician groups across the country.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in CVS Health?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze CVS Health stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
